phase II trial intraperitoneal cisplatin etoposide salvage treatment minimal residual ovarian carcinoma phase II study intraperitoneal IP cisplatin CDDP etoposide salvage therapy patients ovarian cancer persistent disease primary systemic chemotherapy residual disease cm eleven courses IP chemotherapy CDDP patients intravenous IV thiosulfate protection Treatment weeks median cycles assessable patients free disease end treatment normal physical exam tomographic CT scan peritoneal cytology patient partial response patients reexploration end treatment pathologic complete remission patient positive peritoneal washings evidence persistent disease median survival patients months first day IP treatment months diagnosis major toxicity myelosuppression median nadir WBC granulocyte platelet counts cumulative renal damage hypomagnesemia chemical peritonitis IP CDDP pathologic complete remissions second-line regimen patients ovarian cancer systemic cisplatin-based therapy cm disease 